@misc{indiciae50762438d205,
  title = {Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass).},
  author = {Richard Riedel and Malte Verheyen and Sebastian Michels and Lea Ruge and Sofia Stilianakis and Carolin Jakob and Heather Scharpenseel and Matthias Scheffler and Lucia Nogova and Karsten Schulmann and Farastuk Bozorgmehr and Christian Grohe and Frank Griesinger and Vanessa Welter and Jana Fassunke and Janna Siemanowski-Hrach and Yuri Tolkach and Udo Siebolts and Sabine Merkelbach-Bruse and Reinhard B\&\#xfc;ttner and J\&\#xfc;rgen Wolf and Felix John},
  year = {2026},
  doi = {10.1016/j.cllc.2026.08.001},
  url = {https://pubmed.ncbi.nlm.nih.gov/42710416/},
  note = {Source identifier: 42710416}
}